In this large real-world cohort of individuals with type 2 diabetes and bipolar disorder, initiation of SGLT-2 inhibitor therapy was associated with a significantly lower risk of suicide-related events compared to initiation of a DPP-4 inhibitor. Here, SLC5A2 is linked to type 2 diabetes mellitus.